Key Highlights

  • BioMarin shares are trading at $57.71 in Friday's session, down 1.25%, despite new long-term data.
  • Five-year Phase 3 extension data showed durable motor function and relative pulmonary stabilization in late-onset Pompe disease, with no new safety signals.
  • Among 82 patients treated continuously, 51.2% had treatment-related adverse events and five discontinued for safety reasons.
  • Investors are also weighing the Amicus integration, a Royalty settlement and a reported Job consolidation.

Five-Year Pompe Data Fails to Lift the Shares

BioMarin (NASDAQ:BMRN), the San Rafael, California rare disease drugmaker founded in 1997 and Marketing nine therapies, is slipping in Friday's session even after presenting five-year Phase 3 extension data for Pombiliti plus Opfolda in late-onset Pompe disease at the World Muscle Society Congress. The shares are down 1.25% at $57.71, in a choppy market where 10-year Treasury yields above 5.3% and oil near $100 add pressure.

The therapy came to BioMarin through its December Acquisition of Amicus Therapeutics, which expanded the company's presence in rare metabolic disease.

What the Long-Term Numbers Actually Show

The analysis followed 82 patients treated continuously from the start of the original study to year five. Among 62 who had previously received enzyme replacement therapy, the walking distance measure changed by plus 0.7% of predicted, and predicted forced vital capacity declined 2.8%. Among 20 treatment-naive patients followed to year 4.5, walking distance rose 10.5% and forced vital capacity fell 4.4%.

The company described the result as sustained motor function and relatively stable breathing capacity in a progressive disease.

Manageable Events and Five Safety Discontinuations

No new safety signals were identified. About 51.2% of participants, or 42 patients, had treatment-related adverse events, most of them manageable, and five discontinued treatment for safety reasons, including two with serious events: one involving chills and low oxygen and one an anaphylactoid reaction. Separately, the company presented early Phase 1/2 data for nivudirsen, a Duchenne muscular dystrophy therapy for boys with exon 51-amenable disease, which showed expression of near full-length dystrophin and was generally well tolerated.

Can Rare Disease Data Outweigh Integration and Margin Risk?

The question is whether steady clinical evidence matters more to the stock than the Business issues around it. Investors are weighing the integration of Amicus, margin risk, a reported consolidation of 119 jobs, an enzyme-design collaboration with an AI company and a royalty settlement tied to a competing achondroplasia treatment, at 20% in the U.S. and 18% elsewhere through May 2030.

Friday's small drop suggests the five-year data was largely expected and did not change those debates. The consensus target near $89 sits about 54% above the $57.71 price, and the shares remain about 19% below their 52-week high of $70.98, so the gap between analyst expectations and the Market Price is wide.